Holders — by stockHoldings — by fund
Decheng Capital LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0002010850
$731.7M
disclosed book value
14
positions
61.9%
largest position share
Positions, as of 2026-06-30
top 14 of 14 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | CGONCG ONCOLOGY INC | 6.4M | $452.7M | 61.9% |
| 2 | NUVBNuvation Bio Inc. | 26.0M | $147.4M | 20.1% |
| 3 | AARDAARDVARK THERAPEUTICS INC | 3.9M | $22.6M | 3.1% |
| 4 | ACRSAclaris Therapeutics, Inc. | 4.0M | $21.4M | 2.9% |
| 5 | UPBUpstream Bio Inc. | 2.7M | $18.9M | 2.6% |
| 6 | RCUSArcus Biosciences, Inc | 464,779 | $14.3M | 2% |
| 7 | EQEquillium Inc. | 4.4M | $14.2M | 1.9% |
| 8 | RVMDREVOLUTION MEDICINES INC(NSM) | 52,667 | $9.9M | 1.3% |
| 9 | Lyell Immunopharma, Inc. | 692,050 | $9.7M | 1.3% |
| 10 | BeyondSpring Inc. | 3.8M | $6.7M | 0.9% |
| 11 | ZNTLZentalis Pharmaceuticals Inc. | 1.3M | $6.4M | 0.9% |
| 12 | NEWAMSTERDAM PHARMA CO NV | 176,887 | $6.0M | 0.8% |
| 13 | PYXSPyxis Oncology, Inc (formerly Apexigen) | 326,810 | $983,698 | 0.1% |
| 14 | TNGXTANGO THERAPEUTICS INC | 20,000 | $625,200 | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.